Alexion’s Soliris wows in rare disease PhIII trial, opening up a new franchise worth $500M-$700M
Three years after it launched, Alexion $ALXN says that the Phase III study of its cash cow Soliris for rare cases of relapsing neuromyelitis optica …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
